Plasminogen and Plasminogen Activator Assembly on the Human Endothelial Cell

Proceedings of the Society for Experimental Biology and Medicine

Volumn 202, Issue 3, 1993, Pages 258-264

  Shih, Giles C ^a   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANTICOAGULATION; BINDING SITE; BLOOD CLOTTING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBRIN FORMATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SHORT SURVEY; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ANIMAL; BLOOD COAGULATION; CATTLE; ENDOTHELIUM, VASCULAR; HUMAN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RATS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027458531     PISSN: 00379727     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/00379727-202-43534A     Document Type: Article

References (80)

1. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 87:2S–9S, 1989.
2. Stern DM, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 75:272–279, 1985.
3. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 67:362–365, 1986.
4. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 101:363–371, 1985.
5. ++binding to a high affinity site that does not contain gamma-carboxyglutamic acid. J Biol Chem 258:5554–5560, 1983.
6. Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256:5532–5535, 1981.
7. Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 260:2007–2010, 1985.
8. Stern DM, Nawroth PP, Harris K, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C-protein S-mediated inactivation of factor Va. J Biol Chem 261:713–718, 1986.
9. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 66:979–986, 1980.
10. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and the ionophore A 23187. J Clin Invest 62:923–930, 1978.
11. Myers P, Guerra R Jr, Harrison D. Release of NO and EDRF from cultured bovine aortic endothelial cells. Am J Physiol 256:H1030–H1037, 1989.
12. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526, 1987.
13. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 92:181–187, 1987.
14. Glasgow JG, Schade R, Pitlick FA. Evidence that ADP hydrolysis by human cells is related to thrombogenic potential. Thromb Res 13:255–266, 1978.
15. Marcus AJ, Safier LB, Hajjar KA, Ullman HL, Islam N, Broekman MJ, Eiroa AM. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 88:1690–1696, 1991.
16. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 823:35–65, 1985.
17. Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 10:18–23, 1984.
18. Hajjar, KA. Assembly of the fibrinolytic system on endothelial cells. In: Braunwald E, Haber E, Eds. Thrombolysis: Basic Contributions and Clinical Progress. St. Louis, CV Mosby, pp 27–32, 1990.
19. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 74:222–228, 1989.
20. Levin EG, Marotti K, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA. J Biol Chem 264:16030–16036, 1989.
21. Kooistra T, van den Berg J, Tons A. Butyrate stimulates tissue-type plasminogen activator synthesis in cultured human endothelial cells. Biochem J 247:605–612, 1987.
22. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 243:1483–1485, 1989.
23. Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thromb Res 54:41–52, 1989.
24. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type-1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 264:10396–10401, 1989.
25. Van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 60:63–67, 1988.
26. Van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467–1473, 1988.
27. Etingen OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in throm-bogenesis. J Biol Chem 266:2459–2465, 1990.
28. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 257:2912–2919, 1982.
29. Markus G, Evers JL, Hobika GH. Comparison of some properties of native (Glu) and modified (Lys) human plasminogen. J Biol Chem 253:733–739, 1978.
30. Markus G, Priore RL, Wissler FC. The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J Biol Chem 254:1211–1216, 1979.
31. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 26:338–343, 1987.
32. Ichinose A, Kisiel W, Fujikawa K. Proteolytic activation of tissue plasminogen activation by plasma and tissue enzymes. FEBS Lett 175:412–418, 1984.
33. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain prourokinase. J Biol Chem 260:12382–12389, 1985.
34. Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of Glu-plasminogen to Lysplasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest 82:1769–1778, 1988.
35. Schafer AI, Rodriguez R, Loscalzo J, Gimbrone MA Jr. Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin. Blood 74:1015–1020, 1989.
36. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured endothelial cells. J Biol Chem 261:11656–11662, 1986.
37. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266:12752–12758, 1991.
38. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: Identification of α-enolase as a candidate plasminogen receptor. Biochemistry 30:1682–1691, 1991.
39. Kanalas JJ, Makker SP. Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem 266:10825–10829, 1991.
40. Broder CC, Lottenberg R, Von Mering GO, Johnston KH, Boyle MDP. Isolation of a prokaryote plasmin receptor: Relationship to a plasminogen activator produced by the same organism. J Biol Chem 266:4922–4928, 1991.
41. Hajjar KA. The endothelial cell tissue plasminogen activator receptor: Specific interactions with plasminogen. J Biol Chem 266:21962–21970, 1991.
42. Hajjar KA, Hamel NH. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 265:2908–2916, 1990.
43. Scanu AM, Fless GM. Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest 85:1709–1715, 1990.
44. Uterman G. The mysteries of lipoprotein(a). Science 246:904–910, 1989.
45. Loscalzo J. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis 10:672–679, 1990.
46. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu Q-T, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 84:3224–3228, 1987.
47. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132–137, 1987.
48. Weitkamp LR, Guttormsen SA, Schultz JS. Linkage between the loci for the Lp(a) lipoprotein (Lp) and plasminogen (PLG). Hum Genet 79:80–82, 1988.
49. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303–305, 1989.
50. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbati F, Nolli ML, Henkin J, Cines DB. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 265:2865–2872, 1990.
51. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. J Biol Chem 262:4437–4440, 1987.
52. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 261:15819–15822, 1986.
53. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82:4939–4943, 1985.
54. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100:86–92, 1985.
55. Fibbi G, Dini G, Pasquali F, Pucci M, Del Rosso M. The Mr 17,500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells. Biochim Biophys Acta 885:301–308, 1986.
56. Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing V, Cassani G, Appella E, Blasi F. Autocrine saturation of prourokinase receptors on human A431 cells. Cell 45:675–684, 1986.
57. Bajpai A, Baker JB. Cryptic urokinase binding site on human foreskin fibroblasts. Biochem Biophys Res Commun 133:475–482, 1985.
58. Bajpai A, Baker JB. Urokinase binding sites on human foreskin cells. Evidence for occupancy with endogenous urokinase. Biochem Biophys Res Commun 133:994–1000, 1985.
59. Del Rosso M, Dini G, Fibbi G. Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. Cancer Res 45:630–636, 1985.
60. Huarte J., Belin D., Bosco D., Sappino A.P., Vassalli J.D. Plasminogen activator and mouse spermatozoa: Urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface. J Cell Biol 104:1281–1289, 1987.
61. Del Rosso M, Pucci M, Fibbi G, Dini G. Interaction of urokinase with specific receptors abolishes the time of commitment to terminal differentiation of murine erythroleukemia (Friend) cells. Br J Haematol 66:289–294, 1987.
62. Shuman MA, Merkel CH. Urokinase binding to bovine corneal endothelial cells. Exp Eye Res 41:371–382, 1985.
63. Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray S, Behrendt N, Ronne E, Weiner D, Henkin J, Cines DB. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood 76:1795–1806, 1990.
64. Blasi F, Stoppelli MP, Cubellis MV. The receptor for urokinase-plasminogen activator. J Cell Biochem 32:179–186, 1986.
65. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467–474, 1990.
66. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning W-D, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. NH2 terminal amino acid sequence and glycosylation variants. J Biol Chem 265:6453–6460, 1990.
67. Ellis V, Wun TC, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265:9904–9908, 1990.
68. Cubellis MV, Anderson P, Ragno P, Mayer M, Dano K, Blasi F. Accessibility of receptor bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 86:4828–4832, 1989.
69. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9:1079–1085, 1990.
70. Hajjar KA, Hamel NM, Harpel PC, Nachman RL. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 80:1712–1719, 1987.
71. Silverstein RL, Nachman RL, Leung LLK, Harpel PC. Activation of immobilized plasminogen by tissue activator. J Biol Chem 260:10346–10352, 1985.
72. Sanzo MA, Howard SC, Wittwer AJ, Cochrane HM. Binding of tissue plasminogen activator to human aortic endothelial cells. Biochem J 269:475–482, 1990.
73. Reilly TM, Whitfield MD, Taylor DS, Timmermans PB. Binding of tissue plasminogen activator to cultured human fibroblasts. Thromb Haemost 61:454–458, 1989.
74. Morton PA, Owensby DA, Wun TC, Billadello JJ, Schwartz AL. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem 265:14093–14099, 1990.
75. Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/α2 -niacroglobulin receptor is an hepatic receptor for tissue type plasminogen activator. Proc Natl Acad Sci USA 89:7427–7431, 1992.
76. Nguyen G, Self SJ, Camani C, Kruithof EKO. Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff cells. J Biol Chem 267:6249–6256, 1992.
77. Otter M, Barret-Bergshoeff MM, Rijken DC. Binding of tissue-type plasminogen activator by the mannose receptor. J Biol Chem 266:13931–13935, 1991.
78. Parkkinen J, Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin: Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 266:16730–16735, 1991.
79. Beebe DF. Binding of tissue plasminogen activator to human umbilical vein endothelial cells. Thromb Res 46:241–254, 1987.
80. Barnathan ES, Kuo A, Van der Keyl H, McCrae KR, Larsen GR, Cines DB. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct sites. J Biol Chem 263:7792–7799, 1988.